GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MindBio Therapeutics Corp (XCNQ:MBIO) » Definitions » DeferredTaxAndRevenue

MindBio Therapeutics (XCNQ:MBIO) DeferredTaxAndRevenue : C$0.00 Mil (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is MindBio Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

MindBio Therapeutics's current deferred tax and revenue for the quarter that ended in Mar. 2025 was C$0.00 Mil.

MindBio Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for MindBio Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MindBio Therapeutics DeferredTaxAndRevenue Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24
DeferredTaxAndRevenue
- - 0.10 -

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

MindBio Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of MindBio Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


MindBio Therapeutics Business Description

Traded in Other Exchanges
Address
91-97 William Street, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough micro dosing studies. Geographically, the company's activities take place in Australia.
Executives
Accelerative Investments Pty Ltd Director